Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
TURKU, Finland, July 14, 2025 /PRNewswire/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports, demonstrating the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell free DNA of metastatic colorectal cancer patients. Study shows that Bridge Capture™ matches the sensitivity of droplet digital PCR (ddPCR) - a gold standard in the field - while providing unlimited panel scalability and simple and cost-efficient workflow that enables decentralized NGS testing.
The study was performed in collaboration with professor Ari Ristimäki's group (Helsinki University Hospital) and demonstrated a high concordance of Bridge Capture™ to ddPCR and Ion AmpliSeq™ while revealing several other, previously unknown oncogenic mutations that reflected disease progression across longitudinal plasma samples. Prof. Ristimäki was impressed by Bridge Capture™'s capability to combine highly scalable, sensitive targeted sequencing with cost-efficiency and ease of use. He sees this as an important advance that could significantly expand the use of liquid biopsies in treatment monitoring.
"Bridge Capture matched or exceeded gold-standard methods in detecting mutations in patient samples. Its ability to track changes over time could be a powerful tool for monitoring cancer progression and relapse." said Simona Adamusová, Doctoral Researcher and co-first author. "This clinical pilot study highlights Bridge Capture's readiness for real-world applications in liquid biopsy," added Manu Tamminen, CEO and Co-Founder of Genomill. "The unparalleled simplicity of the laboratory workflow and the compatibility across multiple sequencing platforms lays ground for distributed, decentralized, longitudinal cancer diagnostics. By removing cost and infrastructural constraints that currently hinder the routine use of liquid biopsies, we seek to establish Bridge Capture as an enabling technology for highly accessible cancer diagnostics."
Bridge Capture™ is an embodiment of Genomill's Geno1 ® technologies that are based on circular DNA and linear DNA amplification. Juha-Pekka Pursiheimo, CTO and inventor of the technology, added: "Bridge Capture establishes a new standard for NGS library design by using circular single-stranded DNA - a more flexible and robust alternative to traditional linear libraries. Together with our PCR-free DNA amplification approaches, this positions Genomill to revolutionize NGS library preparation."
The full study, titled "Evaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients", is available in Scientific Reports (link ).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
14 hours ago
- Korea Herald
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fibrillation
SEOUL, South Korea, July 18, 2025 /PRNewswire/ -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension. It will be conducted as a multicenter, prospective, single-arm, open-label exploratory study. HyperQure™ is a next-generation laparoscopic RDN device developed over the past decade under the leadership of Professor Chang-Wook Jeong at Seoul National University Hospital. By adopting an extravascular approach, HyperQure™ addresses key limitations of conventional intravascular RDN, offering direct anatomical access to renal nerves with the potential for improved precision and outcomes. DeepQure is also conducting RDN clinical trials for resistant hypertension in both South Korea and the United States. Patient enrollment is nearing completion domestically, while trials are actively underway at five major academic medical centers across the U.S. The MFDS's approval for this new indication marks an important milestone, expanding HyperQure™'s potential from hypertension to atrial fibrillation and reinforcing its technical scalability and multi-disease therapeutic potential. HyperQure™ is ISO 13485–certified, GMP-compliant, and was designated as Innovative Medical Device No. 36 by the MFDS, underscoring its clinical relevance and breakthrough innovation. "This approval validates HyperQure™ as a next-generation solution that overcomes the limitations of traditional RDN techniques," said a DeepQure spokesperson. "With parallel trials in resistant hypertension and now atrial fibrillation, we are accelerating our push into the global cardiovascular market with a truly differentiated solution." About DeepQure DeepQure is a medical technology company pioneering minimally invasive therapies for cardiovascular and autonomic nervous system disorders. Founded by experts in clinical medicine, engineering, and global healthcare, the company is focused on developing breakthrough solutions that address unmet needs in cardiovascular diseases. DeepQure is headquartered in Seoul, South Korea, with clinical programs active in both Korea and the United States. About HyperQure™ RDN System HyperQure™ is DeepQure's proprietary laparoscopic renal denervation (RDN) system designed to treat conditions such as resistant hypertension and atrial fibrillation. Unlike conventional intravascular approaches, HyperQure™ utilizes an extravascular route to access and ablate renal nerves with enhanced precision. The system has been designated as an Innovative Medical Device by the Korean MFDS and has obtained ISO 13485 and GMP certifications, enabling global clinical deployment.
Korea Herald
a day ago
- Korea Herald
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy—pursuing both global procurement channels and direct market entry initiatives. To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment. GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system. From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching approximately USD 300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market [1], with demand for private vaccinations continuing to grow steadily. "This marketing authorization represents more than a product export—it is the result of a localization strategy and a significant step toward expansion in Southeast Asia," said Jae Woo Lee, Head of Development Department at GC Biopharma. "We will continue to strengthen our position as a trusted vaccine brand by delivering clinical and quality standards that meet global expectations." BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterized by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilizing a fully aseptic manufacturing process. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo ® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Sohee Kim Yelin Jun
Korea Herald
3 days ago
- Korea Herald
PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
GARDEN GROVE, Calif., July 16, 2025 /PRNewswire/ -- PHASE Scientific, a fast-growing biotech company known for its science-driven innovation and commitment to improving healthcare outcomes, today announced that it has entered into an exclusive U.S. distribution agreement with Lumos Diagnostics for FebriDx ®, a rapid point-of-care (POC) test that aids in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in approximately 10 minutes using a single drop of blood. With strong product differentiation, FDA 510(k) clearance, and an anticipated CLIA waiver application within the next three months, FebriDx ® is poised to transform how clinicians diagnose and manage respiratory infection. FebriDx ® will become part of PHASE Scientific's INDICAID ® portfolio – a trusted brand for high-quality, accessible rapid diagnostics. The partnership marks a significant milestone in PHASE's commercial expansion in the United States, building upon a nationwide network of urgent care centers, clinics, and healthcare providers and a proven track record of distributing over 100 million INDICAID ® tests. "We are thrilled to partner with Lumos, a company that shares our commitment to shaping the future of healthcare through innovation and collaboration, and support them with our scalable go-to-market strength in North America," said Dr. Ricky Chiu, Founder and CEO of PHASE Scientific. "A powerful complement to our INDICAID ® respiratory portfolio, FebriDx ® is a first-in-class diagnostic that perfectly aligns with our mission to bring fast, actionable diagnostics to the frontlines of care. We are confident this will unlock synergistic opportunities, further advancing our impact on antimicrobial stewardship and clinical decision-making across the U.S. As we continue to expand the INDICAID ® brand, we remain dedicated to strengthening our leadership in point-of-care solutions, empowering clinicians, and improving access to high-quality healthcare." Doug Ward, CEO of Lumos Diagnostics, commented, "This distribution agreement reflects a pivotal moment in Lumos' evolution. We look forward to working with the PHASE Scientific team to ensure that FebriDx ® secures adoption in the U.S. market, delivering tangible clinical and financial value to the broader healthcare system. This agreement also validates the value of the FebriDx ® technology and provides a clear pathway to the U.S. market, which we expect will accelerate rapidly should we receive a grant for CLIA waiver from the FDA. Transforming Respiratory Infection Diagnosis FebriDx ® fills this diagnostic gap with a rapid, point-of-care test that uses a unique combination of C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to aid in the diagnosis of bacterial from non-bacterial respiratory infections after 10 minutes. Its lateral flow format requires only a fingerstick blood sample and has been validated in a pivotal clinical study and demonstrated good diagnostic performance that can, in turn, improve diagnostic confidence and antibiotic stewardship decisions. By enabling faster, more informed treatment decisions, FebriDx ® supports more targeted care in busy patient settings – currently including urgent and emergency care. A CLIA waiver study is progressing well, with anticipated study completion and application submission expected within the next three months. This would expand access to FebriDx ® across a broader range of outpatient environments, representing a market opportunity of approximately US$1.5 billion. Driving Antimicrobial Stewardship FebriDx ® plays a critical role in aiding in addressing the global threat of antimicrobial resistance (AMR), which continues to strain public health systems and drive avoidable costs. By providing rapid, actionable results at the point of care, FebriDx ® helps reduce unnecessary antibiotic prescribing – a key contributor to AMR – and improves clinical workflows by supporting more accurate triage and treatment. Clinical studies have demonstrated that integrating FebriDx ® can lead to reduced antibiotic use, lower healthcare costs, and better patient outcomes. Its unique ability to guide appropriate prescribing makes it a valuable tool in everyday patient care. Strengthening U.S. Market Presence This agreement represents a major step in PHASE Scientific's strategy to reinforce its dual strengths in R&D innovation and commercial execution, as well as accelerate its leadership in the U.S. diagnostics market. Known for its proprietary PHASIFY™ technology and innovation pipeline in cancer and infectious disease diagnostics, PHASE Scientific is now demonstrating its scalable go-to-market strength in North America. About PHASE Scientific PHASE Scientific International Limited ("PHASE Scientific") is a fast-growing biotech company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management. PHASE Scientific's products and services have received certifications from the U.S. Food and Drug Administration (FDA), the European Union CE, and regulatory agencies in various countries, providing over 100 million testing products and services in more than 30 countries worldwide. PHASE Scientific has recently completed a US$34 million Series A funding round, representing the largest Series A raise in Asia's diagnostic technology sector since 2019. Other supporters include Gates Foundation, and US governmental agencies National Science Foundation and National Institutes of Health. For more information, please visit FebriDx ® is a unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes. By aiding clinicians make faster, better decisions at the point-of-care, FebriDx ® has the potential to improve patient outcomes, reduce unnecessary antibiotic prescriptions, and lower overall healthcare costs – all while addressing the urgent global challenge of antimicrobial resistance (AMR). About Lumos Diagnostics Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.
